Koers Fluicell AB (publ) Nasdaq Stockholm
Aandelen
SE0010831321
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 3,25 mln. 301K 279K | Omzet 2023 | 3,34 mln. 309K 286K | Marktkapitalisatie | 17,2 mln. 1,59 mln. 1,48 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -21 mln. -1,94 mln. -1,8 mln. | Nettowinst (verlies) 2023 | -26 mln. -2,4 mln. -2,23 mln. | EV/omzet 2022 | 4,2 x |
Nettoliquiditeiten 2022 | 24,46 mln. 2,26 mln. 2,1 mln. | Nettoliquiditeiten 2023 | 2,76 mln. 255K 237K | EV/omzet 2023 | 4,33 x |
K/w-verhouding 2022 |
-1,89
x | K/w-verhouding 2023 |
-0,62
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 97,97% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Carolina Trkulja
CEO | Chief Executive Officer | 40 | - |
Founder | 44 | 02-01-12 | |
Director of Finance/CFO | 54 | 01-07-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jan Orwar
BRD | Director/Board Member | 60 | 01-01-15 |
Daniel T. Chiu
BRD | Director/Board Member | 52 | 01-01-17 |
Stefan Tilk
CHM | Chairman | 59 | 01-01-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+19,87% | 46,81 mld. | |
-0,62% | 41,37 mld. | |
+47,07% | 41,29 mld. | |
-6,20% | 28,87 mld. | |
+11,75% | 26,06 mld. | |
-19,55% | 19,13 mld. | |
+32,66% | 12,39 mld. | |
+0,40% | 12,08 mld. | |
+0,35% | 11,96 mld. |